c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
CMND
Clearmind Medicine Inc. Common Shares
stock
NASDAQ
Market Open
Nov 18, 2026 9:30:17 AM EST
3.44
USD
-0.290%
(-0.01)
2,071
Pre-market
After-hours
2.5100
Bid
3.6500
Ask
1.1400
Spread
Overview
Company
Exchanges
Shorts
News
News
CMND News
1
/
1
Nov 19, 2026
Day breaks
Nov 19, 2026
08:27 AM EST
Clearmind Medicine (CMND) Files Psychedelic Patent in Hong Kong to Address PTSD
·
GuruFocus
07:32 AM EST
Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication
·
GlobeNewswire Inc.
Nov 16, 2026
07:37 AM EST
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
·
GlobeNewswire Inc.
Nov 10, 2026
07:32 AM EST
Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit
·
GlobeNewswire Inc.
Oct 27, 2026
08:22 AM EDT
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
·
GlobeNewswire Inc.
Oct 12, 2026
07:55 AM EDT
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
·
GlobeNewswire Inc.
Oct 8, 2026
07:32 AM EDT
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
·
GlobeNewswire Inc.
Oct 7, 2026
08:40 AM EDT
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
·
GlobeNewswire Inc.
Sep 23, 2026
09:03 AM EDT
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations
·
NewMediaWire
07:57 AM EDT
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
·
GlobeNewswire Inc.